A Phase 4 interventional study of Estetrol/Drospirenone in Ovarian Endometrioma and Endometrioma, sponsored by Andrew Zakhari. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Andrew Zakhari · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.
Among the 34 studies in Endometriosis with a site in Canada, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2024, is the only one in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 24th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18–45 · Women only
Trio Fertility · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
University of Ottawa · Sites in Canada
Ages 18–60 · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 64 across the 23 interventional studies, 126 across the 11 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Andrew Zakhari as lead sponsor.
Andrew Zakhari has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Endometriosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05643131Hyivy Health IncHyivy Device as Non-hormonal Therapy in Endometriosis | 2026-12 |
| NCT05523284McMaster UniversityCombining Ultrasound and Biomarkers to Diagnose Superficial Endometriosis | 2026-12-30 |
| NCT07713797Trio FertilityBiomarkers for Endometriosis | 2027-01-01 |
| NCT07731776Université de SherbrookeImproving Access to Pelvic Health Physiotherapy for Endometriosis | 2027-03-29 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 34 studies in Endometriosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women. Up to 50% of patients with endometriosis have ovarian endometriomas (or "chocolate cysts"). These cysts directly impact fertility and ovarian reserve (ie. ability to have children) and can cause additional symptoms in women such as added pain, discomfort, and surgical emergencies (cyst rupture, or more rarely twisting). While endometriomas tend to require surgical excision as a solution, medical management with a variety of medications has been shown to be effective in reducing their size.
Medical management (ie. medications and treatments that don't involve surgery) to reduce cyst size can help relieve symptoms either as a long term solution, before fertility treatments, or temporarily until surgery can be offered. Because the COVID-19 pandemic caused significantly reduced access to surgery and resources, medical management has become important for relief of the overburdened healthcare network.
The purpose of this study is to see how effective Estetrol/drospirenone, a combined oral contraceptive (COC), is in the reduction of ovarian endometriomas after a 3- and 6-month period of treatment.
This single arm interventional study will recruit women 18 years or older with an ovarian endometrioma of at least 3cm, who are seeking a hormonal treatment for their endometrioma(s). Consenting participants of the study will take Estetrol/drospirenone once daily, orally, for a 6 month duration. An ultrasound assessment of ovarian endometrioma(s) will be performed before starting the drug (0 months), and will be repeated at 3-months and 6-months time. At each of these hospital visits (0, 3 \& 6 months), participants will have their weight and blood pressure measured, and they will complete questionnaires regarding their endometriosis symptoms, incidence of amenorrhea, compliance and incidence of any adverse effects.
Ovarian endometriomas (or "chocolate cysts") are present in up to 50% of patients with endometriosis - a chronic gynecological disorder associated with pain and infertility. These cysts directly impact fertility and ovarian reserve and can cause additional symptoms in women such as added pain, discomfort, and surgical emergencies (cyst rupture, or more rarely torsion).
While endometriomas tend to require surgical excision for definitive resolution, medical management with a variety of agents has been shown to be effective in reducing their size; these agents include combined oral contraceptives (COC), aromatase inhibitors, progestins, androgens, cabergoline, and gonadotropin-releasing hormone agonists (GnRH-a). Medical management to reduce their size can help alleviate symptoms indefinitely without damaging ovarian reserve prior to fertility treatments, or to temporize until surgical management can be offered. Medical management has become particularly important in light of the COVID-19 pandemic, with significantly reduced access to surgery, and resource allocation to alleviate an overburdened healthcare network.
Estetrol/drospirenone (Nextstellis™) is a prescription-only COC available in Canada containing two hormones: a progestin (drospirenone - well known as both a standalone contraceptive and in other combined formulations), and an estrogen (estetrol - newly introduced with this product). While ethinyl estradiol (EE) is the most common estrogen currently used in COC, estetrol (E4) has proven safety and tolerability, and emerging evidence points towards a lower risk of thrombosis than traditional EE used in other COC. Studies have documented efficacy and safety for the combination estetrol/drospirenone, with a favourable bleeding profile, and very low rates of adverse reactions. While there exists already encouraging data on drospirenone and drospirenone containing products on alleviating symptoms of endometriosis and reducing the size of endometriomas, there are no studies to date evaluating this novel combination of estetrol/drospirenone in managing ovarian endometriomas.
The primary objective of this study is to determine the effectiveness of Estetrol/drospirenone, a combined oral contraceptive (COC), in the reduction of ovarian endometriomas after a 3- and 6-month period of treatment.
This is a single-center, open label, single arm interventional study that will be performed at the McGill University Health Centre (MUHC) Royal Victoria Hospital (RVH). Women 18 years of age or older with at least one ovarian endometrioma, of at least 3cm, who are seeking a hormonal treatment for their endometrioma(s), will be recruited. The study will aim to recruit 21 women.
Consenting participants will be given a 6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration. An ultrasound assessment of ovarian endometrioma(s) will be performed prior to drug initiation (baseline), and will be repeated at 3-months and 6-months time. All ultrasounds will be performed by the same ultrasonographer using a standardized technique and 3-D volumetric assessment. At each of these hospital visits, participants will have their weight and blood pressure measured and they will complete questionnaires regarding their endometriosis symptoms with a research coordinator. Safety, tolerability, and the incidence of adverse effects will also be monitored at the same time intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women 18 years of age or older with endometriosis who have at least one ovarian endometrioma, of at least 3 cm in diameter, who will take oral Drospirenone / Estetrol treatment for 6 months
Drug: Estetrol/Drospirenone
Drug pages: EstetrolStudies of EstetrolEstetrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DrospirenoneStudies of DrospirenoneDrospirenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
Change in ovarian endometrioma volume at 6-months (from baseline)
Endometrioma volume will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.
Time frame: pre-study, 6-months of treatment
Change in endometrioma volume at 3-months (from baseline)
Endometrioma volume will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.
Time frame: pre-study, 3-months of treatment
change in endometrioma maximal diameter at 6-months (from baseline)
Endometrioma maximal diameter will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.
Time frame: pre-study, 6-months of treatment
change in endometrioma maximal diameter at 3-months (from baseline)
Endometrioma maximal diameter will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.
Time frame: pre-study, 3-months of treatment
Incidence of amenorrhea
Incidence of amenorrhea will be evaluated by having the participant complete a questionnaire at each hospital visit. * If they have gotten their period in the last 3 months: measured by (yes/no) * The frequency of spotting in the last month: measured by a 4-point likert scale (Never/Rarely/Occasionally/Often)
Time frame: pre-study, 3-months of treatment, 6-months of treatment
Change in patient reported endometriosis symptoms
Change of endometriosis symptoms will be evaluated by monitoring the changes in participants's responses to the modified Biberoglu \& Behrman (B\&B) scale questionnaire. This is a validated scale that evaluates endometriosis pain by patient's self-assessment of three pain symptoms (dysmenorrhea, dyspareunia, and chronic pelvic pain) on a 4-point likert scale (none=0/mild=1/moderate=2/severe=3). Minimum value: 0 --\> best outcome Maximum value: 9 --\> worst outcome
Time frame: pre-study, 3-months of treatment, 6-months of treatment
Change in weight
Weight will be measured by a research coordinator or nurse at each hospital visit.
Time frame: pre-study, 3-months of treatment, 6-months of treatment
Change in blood pressure
Blood pressure will be measured by a research coordinator or nurse at each hospital visit.
Time frame: pre-study, 3-months of treatment, 6-months of treatment
Incidence of adverse effects (safety, tolerability)
Incidence of adverse effects (yes/no) including: nausea/vomiting, edema, breast tenderness, headache, cramps/bloating, mood swings (specified), as well as any unexpected adverse effects will be evaluated by having the participant complete a questionnaire at each hospital visit after starting estetrol/drospirenone.
Time frame: 3-months of treatment, 6-months of treatment
Compliance
Drug compliance will be evaluated by having the participant complete a questionnaire at each hospital visit after starting estetrol/drospirenone. * If they have been taking the prescribed dosage of 1 oral tablet of estetrol/drospirenone a day (yes/no) * If they have been taking the prescribed dosage at the same time every day (yes/no) * How often they miss a pill, on a 4-point likert scale (Never/Rarely/Occasionally/Often)
Time frame: 3-months of treatment, 6-months of treatment
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2026 → Jul 2027 and completion Dec 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estetrol · Drospirenone